ClinVar Genomic variation as it relates to human health
NM_003002.4(SDHD):c.34G>A (p.Gly12Ser)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
Uncertain significance(1); Benign(18); Likely benign(3)
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_003002.4(SDHD):c.34G>A (p.Gly12Ser)
Variation ID: 6895 Accession: VCV000006895.75
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 11q23.1 11: 112086941 (GRCh38) [ NCBI UCSC ] 11: 111957665 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Apr 12, 2013 Oct 20, 2024 Aug 1, 2024 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_003002.4:c.34G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_002993.1:p.Gly12Ser missense NM_001276503.2:c.34G>A NP_001263432.1:p.Gly12Ser missense NM_001276504.2:c.34G>A NP_001263433.1:p.Gly12Ser missense NM_001276506.2:c.34G>A NP_001263435.1:p.Gly12Ser missense NR_077060.2:n.69G>A non-coding transcript variant NC_000011.10:g.112086941G>A NC_000011.9:g.111957665G>A NG_012337.3:g.5095G>A NG_033145.1:g.4858C>T LRG_9:g.5095G>A LRG_9t1:c.34G>A LRG_9p1:p.Gly12Ser O14521:p.Gly12Ser - Protein change
- G12S
- Other names
-
SDHD, GLY12SER (rs34677591)
- Canonical SPDI
- NC_000011.10:112086940:G:A
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.00499 (A)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
1000 Genomes Project 0.00499
1000 Genomes Project 30x 0.00547
The Genome Aggregation Database (gnomAD) 0.00706
Exome Aggregation Consortium (ExAC) 0.00727
The Genome Aggregation Database (gnomAD), exomes 0.00749
Trans-Omics for Precision Medicine (TOPMed) 0.00804
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
SDHD | Sufficient evidence for dosage pathogenicity | No evidence available |
GRCh38 GRCh37 |
657 | 798 | |
LOC126861339 | - | - | - | GRCh38 | - | 127 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Uncertain significance (1) |
no assertion criteria provided
|
Aug 1, 2008 | RCV000007299.16 | |
Benign (3) |
criteria provided, multiple submitters, no conflicts
|
Jun 9, 2022 | RCV000007300.20 | |
Benign/Likely benign (2) |
criteria provided, multiple submitters, no conflicts
|
Jul 15, 2021 | RCV000007302.19 | |
Benign/Likely benign (6) |
criteria provided, multiple submitters, no conflicts
|
Aug 1, 2024 | RCV000034697.40 | |
Conflicting interpretations of pathogenicity (11) |
criteria provided, conflicting classifications
|
Aug 15, 2023 | RCV000122006.43 | |
Benign (2) |
criteria provided, multiple submitters, no conflicts
|
Aug 21, 2020 | RCV000162470.12 | |
Likely benign (1) |
criteria provided, single submitter
|
May 28, 2019 | RCV000988742.9 | |
Benign (1) |
criteria provided, single submitter
|
Feb 1, 2024 | RCV002228001.14 | |
Benign (1) |
criteria provided, single submitter
|
Jul 15, 2021 | RCV001807000.10 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Benign
(-)
|
criteria provided, single submitter
Method: clinical testing
|
NOT SPECIFIED
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV000309340.1
First in ClinVar: Oct 02, 2016 Last updated: Oct 02, 2016 |
|
|
Benign
(May 25, 2016)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Accession: SCV000698143.1
First in ClinVar: Apr 12, 2013 Last updated: Apr 12, 2013 |
Comment:
Variant summary: The SDHD c.34G>A (p.Gly12Ser) variant involves the alteration of a non-conserved nucleotide. 2/3 in silico tools predict a benign outcome for this variant … (more)
Variant summary: The SDHD c.34G>A (p.Gly12Ser) variant involves the alteration of a non-conserved nucleotide. 2/3 in silico tools predict a benign outcome for this variant (SNPs&GO and MutationTaster not captured due to low reliability index). Functional studies of G12S in the literature have shown mixed results. G12S has been shown to increase ROS levels and activated signaling down the AKT and MAPK pathways, as well as inducing migration and increasing resistance to apoptosis. However, the results of these functional studies may not be a reflection of the in vivo consequence in relation to the PGL/PCC or Cowden Syndrome phenotypes.Population level data suggest that this variant lies in the benign spectrum. Although this variant has been identified in CS, CS-like, and cancer patients, it was also found in 881/121216 control chromosomes (5 homozygotes) at a frequency of 0.007268, which is approximately 4652 times the estimated maximal expected allele frequency of a pathogenic SDHD variant (0.0000016), suggesting this variant is likely a benign polymorphism. Additionally, it was found at an allele frequency of >1% in both the European non-Finnish and other subpopulations of ExAC. Sequence alignment indicates the occurrences in ExAC are unlikely to be from the pseudogenes.Furthermore, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign. Taken together, this variant is classified as benign. (less)
|
|
Benign
(Jul 07, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
germline
|
Eurofins Ntd Llc (ga)
Accession: SCV000332509.4
First in ClinVar: Dec 06, 2016 Last updated: Apr 09, 2018 |
Number of individuals with the variant: 1
Sex: mixed
|
|
Benign
(Apr 23, 2014)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: not provided
Allele origin:
germline
|
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Accession: SCV000206155.5
First in ClinVar: Jan 31, 2015 Last updated: Feb 17, 2019 |
Comment:
Gly12Ser in exon 1 of SDHD: This variant has been identified in 1% (36/3612) of patient chromosomes with varying cancer types that included pheochromocytoma, p … (more)
Gly12Ser in exon 1 of SDHD: This variant has been identified in 1% (36/3612) of patient chromosomes with varying cancer types that included pheochromocytoma, p araganglioma, Cowden and Cowden-like syndromes, and athersclerosis (Gimm 2000, L eube 2004, Ni 2008, Ni 2012, Johnston 2012, Lendavi 2012, Rattenbery 2013). Howe ver, this variant has also been identified in 1.1% (96/8594) European American c hromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu) and 2.5% (6/330) of Puerto Rican and Colombian chromosomes from the 1000 Genomes Project (dbSNP rs34677591). Furthermore, glycine (Gly) at position 12 is not c onserved in mammals or evolutionarily distant species and 5 mammals (tree shrew, vole, hamster, mouse, and rat) carry a serine (Ser) at this position, supportin g that this change may be tolerated. Two studies have shown that this variant ma y modify cancer risk in individuals with pathogenic variants in familial cancer syndrome genes (Ni 2012, Lindavi 2012), though these findings have not been repl icated. In summary, due to the high and equal allele frequency in patient and co ntrol chromosomes and the lack of conservation, this variant is unlikely to cont ribute to Mendelian disease. (less)
Number of individuals with the variant: 1
|
|
Likely benign
(May 28, 2019)
|
criteria provided, single submitter
Method: clinical testing
|
Carney-Stratakis syndrome
Affected status: unknown
Allele origin:
unknown
|
Mendelics
Accession: SCV001138592.1
First in ClinVar: Jan 10, 2020 Last updated: Jan 10, 2020 |
|
|
Benign
(Jul 15, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Paragangliomas 1
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV002054698.1
First in ClinVar: Jan 14, 2022 Last updated: Jan 14, 2022 |
|
|
Benign
(Jul 15, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Pheochromocytoma
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV002054699.1
First in ClinVar: Jan 08, 2022 Last updated: Jan 08, 2022 |
|
|
Benign
(Jul 15, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Mitochondrial complex 2 deficiency, nuclear type 3
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV002054697.1
First in ClinVar: Jan 14, 2022 Last updated: Jan 14, 2022 |
|
|
Benign
(Nov 08, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: no
Allele origin:
germline
|
Genetic Services Laboratory, University of Chicago
Accession: SCV002071034.1
First in ClinVar: Jan 29, 2022 Last updated: Jan 29, 2022 |
|
|
Benign
(Aug 21, 2020)
|
criteria provided, single submitter
Method: curation
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Sema4, Sema4
Accession: SCV002535339.1
First in ClinVar: Jun 24, 2022 Last updated: Jun 24, 2022 |
|
|
Benign
(Nov 06, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
Paragangliomas 1
Affected status: unknown
Allele origin:
unknown
|
Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia
Accession: SCV000297096.3
First in ClinVar: Jul 31, 2016 Last updated: Dec 24, 2022 |
|
|
Benign
(Jun 28, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
unknown
|
Quest Diagnostics Nichols Institute San Juan Capistrano
Accession: SCV000602187.3
First in ClinVar: Mar 08, 2017 Last updated: Dec 31, 2022 |
|
|
Likely benign
(Nov 03, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: not provided
Allele origin:
germline
|
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Accession: SCV002010034.3
First in ClinVar: Nov 06, 2021 Last updated: Jul 16, 2023 |
|
|
Benign
(Aug 15, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: unknown
Allele origin:
germline
|
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Accession: SCV002549992.4
First in ClinVar: Jul 30, 2022 Last updated: Aug 18, 2023 |
|
|
Likely benign
(Jun 14, 2016)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary Paraganglioma-Pheochromocytoma Syndrome
Affected status: unknown
Allele origin:
germline
|
Illumina Laboratory Services, Illumina
Accession: SCV000367342.2
First in ClinVar: Dec 06, 2016 Last updated: Dec 06, 2016 |
|
|
Benign
(Nov 03, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
not specified
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000514600.3
First in ClinVar: Mar 08, 2017 Last updated: Apr 09, 2018 |
Comment:
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at … (more)
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. (less)
|
|
Uncertain significance
(Jan 22, 2020)
|
criteria provided, single submitter
Method: curation
|
Not Specified
Affected status: unknown
Allele origin:
germline
|
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
Accession: SCV001422584.2
First in ClinVar: Jul 19, 2020 Last updated: Jan 29, 2022 |
Comment:
The p.Gly12Ser variant in SDHD has been reported in at least 18 individuals with Cowden or Cowden-like Syndrome (PMID: 21979946, 18678321), 8 individuals with pheochromocytoma … (more)
The p.Gly12Ser variant in SDHD has been reported in at least 18 individuals with Cowden or Cowden-like Syndrome (PMID: 21979946, 18678321), 8 individuals with pheochromocytoma or paraganglioma (PMID: 11156372, 11526495, 12111639, 12386824, 15032977, 23666964), in tumors from 2 individuals (PMID: 12007193), in other cohorts with other phenotypes (PMID: 24728327, 22703879), and has been identified in 1.019% (1316/129110) of European (non-Finnish) chromosomes, including 8 homozygotes, 1.013% (105/10370) of Ashkenazi Jewish chromosomes, including 1 homozygote, and 0.9173% (325/5430) of Latino chromosomes, including 3 homozygotes, by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs34677591). This variant has also been reported in ClinVar as a VUS, likely benign, and benign variant (Variation ID: 6895). Please note that for diseases with clinical variability, or reduced penetrance, pathogenic variants may be present at a low frequency in the general population and pathogenic variants in this gene have incomplete penetrance (PMID: 29386252). In vitro functional studies provide some evidence that the p.Gly12Ser variant may impact growth pathways and apoptosis (PMID: 18678321, 21979946, 25149476). However, these types of assays may not accurately represent biological function and a yeast model did not match a cancer-related phenotype (PMID: 23175444). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. The Glycine (Gly) at position 12 is not highly conserved in mammals and evolutionary distant species, and 5 species (Chinese tree shrew, prairie vole, chinese hamster, mouse, rat) carry a Serine (Ser), supporting that this change at this position may be tolerated. One additional variant, resulting in a different amino acid change at the same position, p.Gly12Asp, has been reported as a VUS in association with disease in ClinVar (Variation ID: 465235). In summary, the clinical significance of the p.Gly12Ser variant is uncertain. ACMG/AMP Criteria applied: BS1, PS4, PS3_Moderate (Richards 2015). (less)
|
|
Benign
(Jun 09, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Paragangliomas 1
Affected status: unknown
Allele origin:
germline
|
Color Diagnostics, LLC DBA Color Health
Accession: SCV004362298.1
First in ClinVar: Feb 14, 2024 Last updated: Feb 14, 2024 |
|
|
Benign
(Oct 14, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Accession: SCV000605088.7
First in ClinVar: Mar 08, 2017 Last updated: Feb 20, 2024 |
|
|
Benign
(Feb 01, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Carney-Stratakis syndrome
Paragangliomas with sensorineural hearing loss Pheochromocytoma Cowden syndrome 3
Explanation for multiple conditions: Uncertain.
The variant was classified for several related diseases, possibly a spectrum of disease; the variant may be associated with one or more the diseases.
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000261731.11
First in ClinVar: Jan 31, 2016 Last updated: Feb 28, 2024 |
|
|
Benign
(May 22, 2015)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV000212833.7
First in ClinVar: Mar 24, 2015 Last updated: May 01, 2024 |
Comment:
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation … (more)
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. (less)
|
|
Benign
(Aug 01, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
CeGaT Center for Human Genetics Tuebingen
Accession: SCV002497177.18
First in ClinVar: Apr 11, 2022 Last updated: Oct 20, 2024 |
Comment:
SDHD: BP4, BS1, BS2
Number of individuals with the variant: 103
|
|
no known pathogenicity
(Jul 13, 2012)
|
no assertion criteria provided
Method: research
|
not provided
Affected status: no
Allele origin:
germline
|
Biesecker Lab/Clinical Genomics Section, National Institutes of Health
Study: ClinSeq
Accession: SCV000043497.1 First in ClinVar: Apr 12, 2013 Last updated: Apr 12, 2013 |
Comment:
Converted during submission to Benign.
Number of individuals with the variant: 9
Comment on evidence:
The study set was not selected for affection status in relation to any cancer. Pathogenicity categories were based on literature curation. See Pubmed ID:22703879 for … (more)
The study set was not selected for affection status in relation to any cancer. Pathogenicity categories were based on literature curation. See Pubmed ID:22703879 for details. (less)
|
|
Likely benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
not provided
Affected status: yes
Allele origin:
germline
|
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Study: VKGL Data-share Consensus
Accession: SCV001800256.1 First in ClinVar: Aug 21, 2021 Last updated: Aug 21, 2021 |
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
not specified
Affected status: yes
Allele origin:
germline
|
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Study: VKGL Data-share Consensus
Accession: SCV001807158.1 First in ClinVar: Aug 27, 2021 Last updated: Aug 27, 2021 |
|
|
Uncertain significance
(Aug 01, 2008)
|
no assertion criteria provided
Method: literature only
|
RECLASSIFIED - VARIANT OF UNKNOWN SIGNIFICANCE
Affected status: not provided
Allele origin:
unknown
|
OMIM
Accession: SCV000027495.7
First in ClinVar: Apr 04, 2013 Last updated: May 01, 2024 |
Comment on evidence:
This variant, formerly titled COWDEN SYNDROME 3, with the Included titles of Intestinal Carcinoid Tumors, Paragangliomas-1, Pheochromocytoma, and Somatic Merkel Cell Carcinoma, has been reclassified … (more)
This variant, formerly titled COWDEN SYNDROME 3, with the Included titles of Intestinal Carcinoid Tumors, Paragangliomas-1, Pheochromocytoma, and Somatic Merkel Cell Carcinoma, has been reclassified based on a review of the ExAC database by Hamosh (2018): the G12S variant was present in 881 of 121,216 alleles and in 5 homozygotes, with an allele frequency of 0.007268 (July 11, 2018). Cowden Syndrome In 4 unrelated patients with a Cowden-like phenotype (see 158350), Ni et al. (2008) identified a heterozygous G12S substitution in the SDHD gene. This mutation was not identified in 700 control subjects. The G12S mutation was associated with increased manganese superoxide dismutase expression, increased reactive oxygen species, and a 1.9-fold increase in both AKT and MAPK expression. All 4 patients were women, ranging in age from 42 to 69 years. Three of 4 manifested breast cancer; 1 had thyroid cancer; 1 had renal cancer; 1 had uterine cancer; and 3 had uterine leiomyomas. Bayley (2011) commented that the findings of Ni et al. (2008) require independent confirmation, and suggested that functional studies of the SDH variants are essential before recommendations can be made for appropriate genetic counseling. Pheochromocytoma/Paraganglioma Syndrome 1 In a patient with an extraadrenal intraabdominal pheochromocytoma (PPGL1; 168000), Gimm et al. (2000) identified a gly12-to-ser (G12S) substitution in the SDHD gene. There was involvement of the jugular fossa, suggesting malignancy, An unrelated patient with an intestinal lipoma had the same mutation. The G12S substitution was identified in 1.3% of control chromosomes, and the authors concluded that it is either a low-penetrance mutation or a rare polymorphism. In a patient with a caudal equina paraganglioma and cerebellar tumors that had developed 22 years later, Masuoka et al. (2001) identified the G12S substitution. There was no family history of paragangliomas. Twenty-one additional cases of spinal paraganglioma had the wildtype SDHD sequence. Cascon et al. (2002) identified the G12S and S68S substitutions in a patient with sporadic pheochromocytoma. However, the G12S substitution was identified in 5 (2.5%) of 200 control chromosomes, and Cascon et al. (2002) concluded that G12S is a polymorphism. In addition, the S68S substitution was found in all 5 controls with the G12S substitution, indicating that the 2 substitutions are in linkage disequilibrium. In a patient with paragangliomas, Perren et al. (2002) identified a heterozygous G12S substitution. Clinical manifestations included a paratracheal paraganglioma, C-cell hyperplasia of the thyroid, and hyperplasia of ACTH-producing cells of the pituitary. There was no family history of the disorder, and the mutation was not identified in 93 controls. Intestinal Carcinoid Tumors and Merkel Cell Carcinoma Kytola et al. (2002) identified a 34G-A transition in exon 1 of the SDHD gene, resulting in the G12S substitution, in the primary tumor of a man diagnosed with nonfamilial midgut carcinoid (see 114900) at 71 years of age. The alteration was also present in the constitutional tissue of the patient, confirming its germline origin. Because the G12S variant led to the elimination of a restriction site for BanI, a restriction cleavage assay was applied to confirm the presence of the change in the patient and to exclude its occurrence in 200 normal individuals. The patient also carried a normally occurring silent polymorphism, ser68-to-ser (S68S), which was previously reported by Baysal et al. (2000). The same G12S missense change accompanied by the S68S polymorphism was also observed by Kytola et al. (2002) in a Merkel cell carcinoma tumor. No normal DNA was available to clarify whether the sequence variants occurred somatically or were present in the germline. To determine whether the tumors with G12S/S68S were associated with a common founder haplotype, Kytola et al. (2002) genotyped 4 microsatellites close to and flanking SDHD. The results excluded the existence of a common founder chromosome. The tumor in the patient with midgut carcinoid showed loss of heterozygosity on genotyping with markers D11S5011 and D11S1986. (less)
|
|
Benign
(-)
|
no assertion criteria provided
Method: clinical testing
|
not specified
Affected status: yes
Allele origin:
germline
|
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Additional submitter:
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Study: VKGL Data-share Consensus
Accession: SCV001955473.1 First in ClinVar: Oct 02, 2021 Last updated: Oct 02, 2021 |
|
|
not provided
(Sep 19, 2013)
|
no classification provided
Method: reference population
|
AllHighlyPenetrant
Affected status: unknown
Allele origin:
germline
|
ITMI
Accession: SCV000086217.1
First in ClinVar: Jun 09, 2014 Last updated: Jun 09, 2014
Comment:
Please see associated publication for description of ethnicities
|
Observation 1:
Ethnicity/Population group: Whole_cohort
Observation 2:
Ethnicity/Population group: African
Observation 3:
Ethnicity/Population group: African_European
Observation 4:
Ethnicity/Population group: Central_Asian
Observation 5:
Ethnicity/Population group: East_Asian
Observation 6:
Ethnicity/Population group: European
Observation 7:
Ethnicity/Population group: Hispanic
|
|
click to load more click to collapse |
Germline Functional Evidence
There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. | Maxwell KN | American journal of human genetics | 2016 | PMID: 27153395 |
Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation. | Yu W | Human molecular genetics | 2015 | PMID: 25149476 |
Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. | Miettinen M | The international journal of biochemistry & cell biology | 2014 | PMID: 24886695 |
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. | Bodian DL | PloS one | 2014 | PMID: 24728327 |
A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. | Rattenberry E | The Journal of clinical endocrinology and metabolism | 2013 | PMID: 23666964 |
Yeast model for evaluating the pathogenic significance of SDHB, SDHC and SDHD mutations in PHEO-PGL syndrome. | Panizza E | Human molecular genetics | 2013 | PMID: 23175444 |
Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. | Johnston JJ | American journal of human genetics | 2012 | PMID: 22703879 |
Over-representation of the G12S polymorphism of the SDHD gene in patients with MEN2A syndrome. | Lendvai N | Clinics (Sao Paulo, Brazil) | 2012 | PMID: 22584711 |
Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. | Ni Y | Human molecular genetics | 2012 | PMID: 21979946 |
Succinate dehydrogenase gene variants and their role in Cowden syndrome. | Bayley JP | American journal of human genetics | 2011 | PMID: 21565294 |
Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. | Ni Y | American journal of human genetics | 2008 | PMID: 18678321 |
SDHD mutation analysis in seven German patients with sporadic carotid body paraganglioma: one novel mutation, no Dutch founder mutation and further evidence that G12S is a polymorphism. | Leube B | Clinical genetics | 2004 | PMID: 15032977 |
Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. | Perren A | Oncogene | 2002 | PMID: 12386824 |
Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma. | Cascon A | European journal of human genetics : EJHG | 2002 | PMID: 12111639 |
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. | Kytölä S | Genes, chromosomes & cancer | 2002 | PMID: 12007193 |
Germline SDHD mutation in paraganglioma of the spinal cord. | Masuoka J | Oncogene | 2001 | PMID: 11526495 |
Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. | Gimm O | Cancer research | 2000 | PMID: 11156372 |
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. | Baysal BE | Science (New York, N.Y.) | 2000 | PMID: 10657297 |
Hamosh, A. Personal Communication. 2018. Baltimore, Md. | - | - | - | - |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SDHD | - | - | - | - |
https://erepo.clinicalgenome.org/evrepo/ui/interpretation/65df1911-d283-477f-ae29-8e2f5c568e24 | - | - | - | - |
click to load more click to collapse |
Text-mined citations for rs34677591 ...
HelpRecord last updated Nov 25, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.